Superdrug Owner Eyes up London Float in $30bn Dual Listing

Why It Matters

The listing would inject fresh equity into a leading UK health‑and‑beauty chain while signaling renewed confidence in the London market, potentially catalyzing further high‑street IPO activity.

Key Takeaways

• AS Watson aims to raise $2 bn via London‑Hong Kong dual IPO.
• Superdrug revenue hit $2.05 bn, profit $175 m despite weak consumer confidence.
• Listing would place Superdrug among a wave of high‑street IPOs in London.
• CK Hutchison’s recent asset sales signal strategic focus on core businesses.
• London market revival faces geopolitical risk from Iran‑related tensions.

Pulse Analysis

AS Watson’s decision to pursue a dual primary listing reflects a strategic pivot toward deeper integration with global capital markets. By targeting both London and Hong Kong, the group taps into the UK’s renewed appetite for retail IPOs and the liquidity of Asian investors, while diversifying its funding sources. The $2 bn raise is modest relative to the $30 bn valuation, but it provides a runway for Superdrug to fund expansion, digital upgrades, and potential acquisitions, positioning the chain to capture post‑pandemic health‑and‑beauty demand.

Superdrug’s latest financials underscore resilience amid a challenging consumer backdrop. Revenue climbed 7% to $2.05 bn and pre‑tax profit surged 23% to $175 m, driven by a robust pharmacy network and a strategic push to create over 600 jobs. These gains come despite lingering inflation pressures and higher interest rates that have squeezed disposable income. The strong performance bolsters investor confidence that the retailer can sustain growth, making the proposed London float an attractive proposition for institutional buyers seeking exposure to a stable, cash‑generating UK retailer.

The move also fits a broader trend of high‑street brands eyeing London listings after a two‑year IPO drought. Boots, Waterstones and the upcoming Primark spin‑off illustrate a collective belief that the UK market can support sizable retail offerings, even as geopolitical uncertainty—most notably the Iran conflict—tempers sentiment. CK Hutchison’s recent divestitures, including its stake in Three, suggest a focus on core, high‑margin assets, further aligning the Superdrug float with a disciplined capital‑allocation strategy. If successful, the listing could reignite investor enthusiasm for UK retail IPOs, while providing a benchmark for future cross‑border offerings.